Avalo Therapeutics grants director 1,352 options
Avalo Therapeutics (AVTX) granted a director 1,352 stock options at $15.33 per share, exercisable from 2026 and expiring in 2036. The options are tied to 1,352 shares of common stock.
How this was made
The 30-second read
Why it matters
The grant is a modest, routine insider compensation that provides limited new information for traders.
Market read
Small insider option grant with low immediate trading relevance.
What to watch
Potential dilution if many similar grants are issued to other insiders.
Background
Form 4 filings disclose insider transactions; a director receiving options is a standard compensation event.
Ticker impact
SEC Form 4 shows a director was granted 1,352 stock options at $15.33 exercise price.
potential slight upside as insider receives options
The filing is a primary disclosure of a small option grant; size is modest, so any price effect is expected to be minimal.
Market effects
None significant for the biotech sector.
Limited to Avalo Therapeutics investors.
Minimal.
Counterpoint
The option grant could be routine compensation with no real upside.
Key entities
- CompanyAvalo Therapeutics, Inc.
Biopharmaceutical company issuing the options.
- IndividualDirector (unnamed)
Recipient of the stock options.
